| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
USP30-IN-20 (Compound 8m) showed significant anti-proliferative activity against PC3, DU145 prostate cancer cells and CD24-CD44+ prostate cancer stem cells, with IC50 values of 4.87 μM, 5.44 μM and 5.94 μM, respectively [1]. USP30-IN-20 (2.5-5 μM, 14 days) significantly reduced the number of malignant clones in PC3 and DU145 cells [1]. USP30-IN-20 (2.5-5 μM, 24-48 h) induced G0/G1 phase arrest in PC3 and DU145 cells, inhibited migration and reduced invasiveness [1]. USP30-IN-20 (2.5-5 μM, 72 h) interfered with tumor spheroid formation and significantly reduced the number of spheroids in PC3 and DU145 cells [1]. USP30-IN-20 (2.5-5 μM, 24 h) significantly upregulated intracellular ROS and lipid ROS levels in PC3 and DU145 cells, increased malondialdehyde (MDA) content, and decreased glutathione (GSH) levels [1]. USP30-IN-20 (5 μM, 24 h) caused mitochondria in PC3 cells to shrink, mitochondrial cristae and membrane structures to disappear, and disrupted mitochondrial membrane potential, but did not affect apoptosis [1]. USP30-IN-20 (2.5-5 μM; 24 h) downregulated GPX4 protein expression in PC3 and DU145 cells in a dose-dependent manner [1].
|
|---|---|
| ln Vivo |
USP30-IN-20 (Compound 8m) (25-50 mg/kg, lateral wall, once daily for 18 days) significantly inhibited ischemia in PC3 hepatocellular carcinoma xenografts in nude mice [1].
|
| Cell Assay |
Cell Invasion Assay[1]
Cell Types: PC3 and DU145 cells Tested Concentrations: 2.5, 5 μM Incubation Duration: 24 h Experimental Results: Suppressed the invasion capacity of PC3 and DU145 cells. |
| Animal Protocol |
Animal/Disease Models: PC3 prostate cancer cells (1 × 107 cells) were subcutaneously implanted into the flanks of 6-8-week-old male athymic nude mice (BALB/c strain)[1]
Doses: 25, 50 mg/kg Route of Administration: p.o., daily, 18 days Experimental Results: Achieved significant tumor growth inhibition in male athymic nude mice. Showed no significant changes in body weight. |
| References |
| Molecular Formula |
C16H15CLO2SE
|
|---|---|
| Molecular Weight |
353.70
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8273 mL | 14.1363 mL | 28.2725 mL | |
| 5 mM | 0.5655 mL | 2.8273 mL | 5.6545 mL | |
| 10 mM | 0.2827 mL | 1.4136 mL | 2.8273 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
